

## Board Meeting Highlights – November 6-7, 2024

The California State Board of Pharmacy took the following actions at its meeting on November 6 – 7, 2024:

- Approved the minutes of the July 31-August 1, 2024 Board meeting, the September 12, 2024 Board meeting, and the August 23, 2024 Disciplinary Petition Committee meeting.
- Consistent with the Board's authority in Business and Professions Code section 4062, extended the current Waiver Related to Temporary Provisions for Compounding Certain Parenteral Drug Products.
- Approved updates to Frequently Asked Questions related to Assembly Bill 1286 (Haney, Chapter 470, Statutes of 2023).
- Approved draft report to the Legislature on automated drug delivery Systems (ADDS).
- Voted to have Enforcement and Compounding Committee chairperson and staff work together to develop potential statutory language related to flavoring agents and prescription requirements.
- Approved the development and deployment of workforce surveys for pharmacists and pharmacy technicians.
- Approved updated training materials on HIV Preexposure and Postexposure Prophylaxis (PrEP and PEP).
- Approved the new issues and draft statutory language that was not previously approved by the Board as consistent with the Board's policy discussions, and further, delegated to the Board president and executive officer to finalize this portion of the sunset review with staff for inclusion in the Board's legislative report.
- Voted to add a new strategic objective for the Enforcement and Compounding Committee, specifically 2.11 – Enhance patient consultation compliance by evaluating barriers to consultation to provide patient education and reduce medication errors.
- Regarding the proposed amendment to California Code of Regulations, title 16, section 1709.1 related to Designation of Pharmacist-in-Charge: Ratified the modifications to the regulatory text published during the second 15-day comment period from October 17, 2024, through November 1, 2024, accepted Board staff recommended comment responses, and directed Board staff to take all steps necessary to complete the rulemaking process.
- Regarding the proposed amendment to California Code of Regulations, title 16, section 1711 related to Quality Assurance Programs: Accepted

Board staff recommended comment responses, approved the recommended updated modified text as recommended by staff for a 15-day comment period, and, if the Board does not receive any comments providing objections or adverse recommendations specifically directed at the proposed action or to the procedures followed by the Board in proposing or adopting the action, authorized the executive officer to take all steps necessary to adopt the proposed regulation and complete the rulemaking process. Further, delegated to the executive officer the authority to make technical or non-substantive changes as may be required by the Control agencies to complete the rulemaking file.

- Regarding the proposed regulations, California Code of Regulations, title 16, repeal of sections 1708.3, 1708.4, 1735 et seq and 1751 et seq and addition of sections 1735 et seq, 1736 et seq, 1737 et seq, and 1738 et seq related to Compounded Drug Preparations, Hazardous Drugs and Radiopharmaceuticals: Accepted the Board staff recommended responses as included in the meeting materials, including the updated supplemental responses, to the initial comments from the 45-day comment period and regulation hearing as the responses of the Board; approved the recommended modified regulation text dated August 29, 2024, as presented, for a 30-day public comment period; and delegated to Members Serpa and Barker the authority to review comments received to the modified text during the public comment period with staff to present recommended changes and responses at a future Board meeting.

Additional information about action items can be found online in the November 6 – 7, 2024 meeting materials on the [Board website](#).

###